Subsequently, we extended the inhibitory receptor analysis to patients after vaccination with Melan-A peptide, with or without the addition of CpG-ODN 7909 to the vaccine formulation (Figures 2A and S2), and compared the data to the other two conditions, i.e. healthy donors and melanoma patients before vaccination. This evidence concerns the gene MLANA and melanoma.